Biopharmx (NYSEAMERICAN:BPMX) Announces Earnings Results, Beats Expectations By $0.12 EPS

Biopharmx (NYSEAMERICAN:BPMX) posted its earnings results on Monday. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.12, Fidelity Earnings reports.

Shares of NYSEAMERICAN:BPMX traded up $0.01 during mid-day trading on Tuesday, reaching $0.40. The stock had a trading volume of 12,489 shares, compared to its average volume of 610,260. Biopharmx has a 1 year low of $0.30 and a 1 year high of $6.75.

Separately, Maxim Group set a $3.00 price objective on Biopharmx and gave the stock a “buy” rating in a research note on Tuesday, June 25th.

In related news, major shareholder Vivo Capital Viii, Llc sold 327,870 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $1.02, for a total value of $334,427.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

About Biopharmx

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Read More: How to track put option volume

Earnings History for Biopharmx (NYSEAMERICAN:BPMX)

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.